RxDoctor Payments Data

Ashley Haggerty, MD

Gynecologic Oncology · Philadelphia, PANPI 1639331028

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,978 of the $7,640 with a category attached, or 78.2%. 17 manufacturers reported payments, led by AstraZeneca at 37.1% of the total.

$7,640in general payments, 2019–2025

Across 61 payments — averaging $125.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$2K
  • Merck$1K
  • Genmab U.S., Inc.$243
  • Davol Inc.$228
  • Myriad Genetic Laboratories, Inc.$177
  • plus $675 from 11 others
$321,007in research payments, 2019–2025

Across 9 payments — averaging $35,667 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$321K

What the payments were for

  • Consulting fees$5,97878%
  • Food & beverage$1,66322%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,640 in reported general payments places this provider in the 75th percentile of 90 gynecologic oncology providers in Pennsylvania.

See all gynecologic oncology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$97,326
Medicare patients
186
Services billed
400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →